Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OMT-28 (OMEICOS Therapeutics)
- Development stage
- Unknown
- Lead developer
- OMEICOS Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**OMT-28** is an investigational, orally administered small-molecule analog of the omega-3 fatty-acid metabolite 17,18-epoxyeicosatetraenoic acid. Developed by OMEICOS Therapeutics, it is designed to reduce mitochondrial dysfunction, oxidative stress, and inflammation through biased modulation of sphingosine-1-phosphate receptor 1 signaling and activation of the AMPK/SIRT1/PGC-1alpha mitochondrial-restoration axis. OMT-28 has completed a Phase 2a study in primary mitochondrial disease with mitochondrial myopathy and/or cardiomyopathy, and OMEICOS has announced plans to advance the program into a pivotal Phase 3 study. ([omeicos.com](https://omeicos.com/pipeline/))
- Other names
- 2-{[(8Z)-13-[(methylcarbamoyl)formamido]tridec-8-en-1-yl]oxy}acetic acid2-[(Z)-13-[[2-(methylamino)-2-oxoacetyl]amino]tridec-8-enoxy]acetic acid
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)PPARA (Peroxisome proliferator-activated receptor alpha)PPARGC1A (Peroxisome proliferator–activated receptor gamma coactivator 1-alpha)SIRT1 (NAD-dependent protein deacetylase sirtuin-1)SIRT3 (NAD-dependent protein deacetylase sirtuin-3)
Beyond the preview
Go deeper on OMT-28 (OMEICOS Therapeutics).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OMT-28 (OMEICOS Therapeutics).